Canada markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
76.39-3.21 (-4.03%)
At close: 04:00PM EST
76.39 0.00 (0.00%)
After hours: 04:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close79.60
Open79.60
Bid76.26 x 1000
Ask100.00 x 900
Day's Range76.25 - 81.40
52 Week Range75.41 - 157.98
Volume581,341
Avg. Volume246,969
Market Cap4.149B
Beta (5Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-4.14
Earnings DateFeb. 28, 2022 - Mar. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est142.90
  • GlobeNewswire

    Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

    – Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 –– Additional indications planned in 2023 – REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast

  • Zacks

    Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?

    Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

  • GlobeNewswire

    Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

    REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021. Recent Accomplishments Presented data at American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting from prospective study showing high prevalence rates